TB Alliance Sublicenses Promising Tuberculosis Drug 全utezolid'

by Shirley Johanna on  March 24, 2017 at 3:28 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

On the World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug that showed promising results in earlier studies.
TB Alliance Sublicenses Promising Tuberculosis Drug 全utezolid'
TB Alliance Sublicenses Promising Tuberculosis Drug 全utezolid'

The sublicense pertains to the development of sutezolid in combination with other TB drugs and is a follow-up of the MPP's license for the treatment, signed in January with patent holder Johns Hopkins University

"There are precious few novel drugs available for TB therapy and therefore every promising new candidate is greeted with much enthusiasm," said Dr. Mel Spigelman, President and CEO of TB Alliance.

"With the additional positive results from our current clinical trials we can thoroughly vet sutezolid in a variety of potentially transformative new TB regimens."

Sutezolid
Sutezolid belongs to the same class of drugs as linezolid (oxazolidinones), which is used to treat drug-resistant TB (DR-TB) in some countries. According to the tests conducted over the past decade, sutezolid may have a better therapeutic potential than linezolid.

"Sutezolid is the first TB drug in the Medicines Patent Pool's portfolio, and we are pleased with TB Alliance's swiftness in sublicensing the candidate," said Greg Perry, Executive Director of the Medicines Patent Pool.

"We are grateful to the civil society coalition that pushed for the clinical development of sutezolid. If further studies are successful, this product could be a game-changer in improving options for patients."

MPP's license with Johns Hopkins University grants the MPP the rights to sublicense sutezolid to product developers interested in further developing the treatment for both drug-susceptible and drug-resistant TB, and to combine sutezolid with a wide variety of other TB drugs.

TB is the world's leading infectious disease killer. In 2015, about 10.4 million people were newly diagnosed with TB and 1.8 million died from the disease, according to the World Health Organization. An estimated 580,000 patients were deemed eligible for MDR-TB treatment in 2015. The success rate of MDR-TB treatment is only 52 percent.

"UNITAID strongly supports the TB Alliance-Medicines Patent Pool collaboration to jump-start the clinical development of the new tuberculosis treatment sutezolid," said Lelio Marmora, Executive Director of UNITAID, the MPP's funder. "This World Tuberculosis Day, we must re-double efforts to find better, faster-acting treatment solutions, especially for resistant forms of the disease."



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Recommended Reading

More News on:

Drug Toxicity Tuberculosis AIDS/HIV Tracheostomy Signature Drug Toxicity Pleural Effusion Drugs Banned in India Silicosis Screening Tests for Tuberculosis Fever 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive